Biotechnology company Advanced Enzyme Technologies announced consolidated Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue from Operations: Revenue from operations on consolidated basis increased to Rs 1,578 million in the Q4FY24 from Rs 1,387 million in the Q4FY23, a growth of 14%. Profit: Consolidated EBITDA during Q4FY24 stands at Rs 554 million as compared to Rs 441 million during Q4FY23, an increase of 26%. Profit before tax stands at Rs 397 million during Q4FY24 as against Rs 421 million in Q4FY23, decrease of 6%. Profit after tax de-grew by 7% and stands at Rs 299 million during Q4FY24 as compared to Rs 321 million during the Q4FY23. Margin: EBITDA margin stands at 35%, PBT margin stands at 25% and PAT margin stood at 19% during the quarter. Financial Costs: Financial costs stood at Rs 8 million during Q4FY24 as against Rs 6 million in Q4FY23. Depreciation and Amortization: Depreciation and Amortization charge for the Q4FY24 stood at Rs 93 million as compared to Rs 84 million, the same quarter previous year. Earnings Per Share: Earnings Per Share during Q4FY24 stands at Rs 2.53 as compared to Rs 2.87 in Q4FY23. FY24 Financial Highlights: Revenue from Operations: Revenue from operations on consolidated basis increased to Rs 6,239 million in the FY24 from Rs 5,406 million in the FY23, reported an increase of 15%. Profit: Consolidated EBITDA during FY24 stands at Rs 2,045 million as compared to Rs 1,546 million during FY23, growth of 31%. Profit before tax stands at Rs 1,879 million during FY24 as against Rs 1,404 million in FY23, an increase of 34% Profit after tax stands at Rs 1,370 million during FY24 as compared to Rs 1,039 million during the FY23, an increase of 32%. Margin: EBITDA margin stands at 33%, PBT margin stands at 30% and PAT margin stands at 22% during the FY24. Financial Costs: Financial costs stood at Rs 29 million during FY24 as against Rs 24 million in FY23. Depreciation and Amortization: Depreciation and Amortization charge for the FY24 is Rs 353 million as compared to Rs 350 million in FY23. Earnings Per Share: Earnings Per Share during FY24 stands at Rs 11.92 as compared to Rs 9.45 in FY23. Result PDF
Conference Call with Advanced Enzyme Technologies Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.
Biotechnology company Advanced Enzyme Technologies announced Q1FY24 results: Revenue from operations on a consolidated basis increased to Rs 1,473 million in Q1FY24 from Rs 1,211 million in Q1FY23, a growth of 22%. Consolidated EBITDA during Q1FY24 stands at Rs 440 million as compared to Rs 309 million during Q1FY23, an increase of 42%. Profit before tax stands at Rs 414 million during Q1FY24 as against Rs 237 million in Q1FY23, an increase of 75%. Profit after tax grew by 67% and stands at Rs 294 million during Q1FY24 as compared to Rs 176 million during Q1FY23. EBITDA margin stands at 30%, PBT margin stands at 28% and PAT margin stands at 20% during Q1FY24. Financial costs stood at Rs 7 million during Q1FY24 as against Rs 6 million in Q1FY23. Depreciation and Amortization charges for Q1FY24 remain unchanged at Rs 86 million as compared to Q1FY23. Earnings Per Share during Q1FY24 stands at Rs 2.58 as compared to Rs 1.60 in Q1FY23. Result PDF
Biotechnology company Advanced Enzyme Technologies announced Q4FY23 & FY23 results: Consolidated Q4FY23 (YoY basis): Revenue from operations increased to Rs 1,387 million in Q4FY23 from Rs 1,317 million in Q4FY22, recording a growth of 5% EBITDA during Q4FY23 stands at Rs 441 million as compared to Rs 403 million during Q4FY22, increase of 6% Profit before tax stands at Rs 421 million during Q4FY23 as against Rs 340 million in Q4FY22, up by 24% Profit after tax grew by 27% and stands at Rs 321 million during Q4FY23 as compared to Rs 253 million during Q4FY22 EBITDA margin stands at 32%, PBT margin stands at 30% and PAT margin stands at 23% during Q4FY23 Financial costs stood at Rs 6 million during Q4FY23 as against Rs 7 million in Q4FY22 Depreciation and Amortization charge for Q4FY23 is Rs 84 million as compared to Rs 91 million in Q4FY22 Earnings Per Share during Q4FY23 stands at Rs 2.87 as compared to Rs 2.19 in Q4FY22 Consolidated FY23: Revenue from operations increased to Rs 5,406 million in the FY23 from Rs 5,294 million in the FY22, reported a growth of 2% EBITDA during FY23 stands at Rs 1,546 million as compared to Rs 2,014 million during FY22, down 22% Profit before tax stands at Rs 1,404 million during FY23 as against Rs 1,711 million in FY22 Profit after tax stands at Rs 1,039 million during FY23 as compared to Rs 1,238 million during the FY22 EBITDA margin stands at 29%, PBT margin stands at 26% and PAT margin stands at 19% during the FY23 Financial costs stood at Rs 24 million during FY23 as against Rs 18 million in FY22 Depreciation and Amortization charge for the FY23 remained flat at Rs 350 million Earnings Per Share during FY23 stands at Rs 9.45 as compared to Rs 10.70 in FY22 Result PDF
Biotechnology firm Advanced Enzyme Technologies announced Q3FY23: Consolidated Q3FY23: Revenue from operations: Revenue from operations on a consolidated basis climbed to Rs 1,421 million in Q3FY23 from Rs 1,387 million in Q2FY23, a growth of 02%. Profit: Consolidated EBITDA during Q3FY23 stands at Rs 417 million as compared to Rs 397 million during Q2FY23, increase of 05%. Profit before tax stands at Rs 404 million during Q3FY23 as against Rs 342 million in Q2FY23, growth of 18% Profit after tax grew by 06% and stands at Rs 279 million during Q3FY23 as compared to Rs 263 million during Q2FY23. Financial costs remained flat to stand at Rs 06 million during Q3FY23 Depreciation and Amortization: Depreciation and Amortization charge for Q3FY23 is Rs 91 million as compared to Rs 88 million in the last quarter. Earnings Per Share: Earnings Per Share during Q3FY23 stand at Rs 2.63 as compared to Rs 2.34 in Q2FY23. Consolidated 9MFY23: Revenue from Operations: Revenue from operations on a consolidated basis increased to Rs 4,019 million in the 9MFY23 from Rs 3,976 million in the 9MFY22, reported a growth of 01%. Profit: EBITDA during 9MFY23 stands at Rs 1,123 million as compared to Rs 1,611 million during 9MFY22, decline of 30%. Profit before tax stands at Rs 983 million during 9MFY23 as against Rs 1,371 million in 9MFY22 Profit after tax stands at Rs 718 million during 9MFY23 as compared to Rs 985 million during the 9MFY22. Margin: EBITDA margin stands at 28%, PBT margin stands at 24% and PAT margin stands at 18% during the 9MFY23 Financial Costs: Financial costs stood at Rs 18 million during 9MFY23 as against Rs 11 million in 9MFY22. Depreciation and Amortization: The depreciation and amortization charge for the 9MFY23 is Rs 266 million as compared to Rs 259 million in 9MFY22. Earnings Per Share: Earnings Per Share during 9MFY23 stands at Rs 6.57 as compared to Rs 8.51 in 9MFY22. Result PDF